Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


ucin1211828943.pdf (478.29 KB)

ETD Abstract Container

Abstract Header

A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal

WEIMERT, NICOLE A.
http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211828943

Abstract Details

2008, MS, University of Cincinnati, Medicine : Epidemiology (Environmental Health).
In 2005, greater than 16,000 kidney transplants were performed in the United States, with 68% of grafts functioning at 5 years (United Organ Sharing Network). Current immunosuppression regimens require long-term exposure to corticosteroids which are associated with an increased incidence of cardiovascular disease, obesity, and worsening diabetes control leading to early patient and graft loss. Combined with the increasing incidence of end-stage renal disease and subsequent need for transplantation, optimization of current immunosuppression is needed to ensure long-term patient and graft outcomes. Minimizing corticosteroids requires adequate exposure to mycophenolic acid to maintain the net level of immunosuppression needed to prevent rejection and graft loss. We will determine the pharmacokinetic profile of mycophenolic acid in a corticosteroid withdrawal protocol and will assess the pharmacodynamic relationship between inosine monophosphate dehydrogenase activity and mycophenolic acid inhibition peri-transplant based on the rate of acute rejection and incidence of adverse effects.
Paul Succop, PhD (Committee Chair)
Rita Alloway (Committee Member)
E. Steve Woodle (Committee Member)
Alexander Vinks (Committee Member)
54 p.
Health Care
mycophenolic acid; pharmacokinetic; kidney; transplant

Recommended Citations

Citations

  • WEIMERT, N. A. (2008). A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal [Master's thesis, University of Cincinnati]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211828943

    APA Style (7th edition)

  • WEIMERT, NICOLE. A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal. 2008. University of Cincinnati, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211828943.

    MLA Style (8th edition)

  • WEIMERT, NICOLE. "A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal." Master's thesis, University of Cincinnati, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211828943

    Chicago Manual of Style (17th edition)

ucin1211828943
627
© 2008, all rights reserved.
This open access ETD is published by University of Cincinnati and OhioLINK.